Trial Profile
Randomized phase III study of nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Nedaplatin
- Indications Lung cancer
- Focus Therapeutic Use
- 27 Oct 2015 Results published in the Lancet Oncology
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.